Vitamin D deiciency and its relation to bone mineral density and liver ibrosis in HIV-HCV coinfection

Antiviral Therapy

Volumn 18, Issue 2, 2013, Pages 237-242

  El Maouche, Diala ^a   Mehta, Shruti H ^b   Sutcliffe, Catherine G ^b   Higgins, Yvonne ^c   Torbenson, Michael S ^c   Moore, Richard D ^b,c   Thomas, David L ^c   Sulkowski, Mark S ^c   Brown, Todd T ^c  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; EFAVIRENZ; INTERFERON; PARATHYROID HORMONE; RIBAVIRIN; STAVUDINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ADULT; AFRICAN AMERICAN; ARTICLE; BONE DENSITY; CD4 LYMPHOCYTE COUNT; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; HYPERPARATHYROIDISM; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SCORING SYSTEM; STAGING; VITAMIN D DEFICIENCY; Z SCORE; LIVER CIRRHOSIS; MIDDLE AGED; PREVALENCE; RISK FACTOR;

AFRICAN AMERICANS; BONE DENSITY; COINFECTION; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS; VITAMIN D DEFICIENCY;

EID: 84875656279     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2264     Document Type: Article

References (24)

1. Petta S, Camma C, Scazzone C, et al. Low vitamin D serum level is related to severe ibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology 2010; 51:1158-1167.
2. Terrier B, Carrat F, Geri G, et al. Low 25-OH vitamin D serum levels correlate with severe ibrosis in HIV-HCV co-infected patients with chronic hepatitis. J Hepatol 2011; 55:756-761.
3. Bedimo RWA, Drechsler H, Maalouf N. HCV co-infection is associated with a high risk of osteoporotic fractures among HIV-infected patients. 18th International AIDS Conference. 18-23 July 2010, Vienna, Austria. Abstract TUAB01042010.
4. Hansen AB, Gerstoft J, Kronborg G, et al. Incidence of low and high-energy fractures in persons with and without HIV infection: a Danish population-based cohort study. AIDS 2012; 26:285-293.
5. Young B, Dao CN, Buchacz K, Baker R, Brooks JT. Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000-2006. Clin Infect Dis 2011; 52:1061-1068.
6. Targher G, Bertolini L, Scala L, et al. Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2007; 17:517-524.
7. El-Maouche D, Mehta SH, Sutcliffe C, et al. Controlled HIV viral replication, not liver disease severity associated with low bone mineral density in HIV/HCV co-infection. J Hepatol 2011; 55:770-776.
8. Egan KM, Signorello LB, Munro HM, Hargreaves MK, Hollis BW, Blot WJ. Vitamin D insuficiency among African-Americans in the southeastern United States: implications for cancer disparities (United States). Cancer Causes Control 2008; 19:527-535.
9. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24:289-293.
10. Bedossa P. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994; 20:15-20.
11. Hologic I. Hologic Data Dictionary and Calculations. Bedford, MA, USA 2000.
12. Hologic I. Ethnic Normals Reference Database. Bedford, MA, USA 2007.
13. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. In Dawson-Hughes B, Lindsay R, Khosla S, Melton LJ, Tosteton AN, Favus M, Baim S (Editors). Washington, DC: National Osteoporosis Foundation 2010; pp. 12.
14. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006; 20:2165-2174.
15. Dao CN, Patel P, Overton ET, et al. Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D Levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clin Infect Dis 2011; 52:396-405.
16. Lips P, Duong T, Oleksik A, et al. A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial. J Clin Endocrinol Metab 2001; 86:1212-1221.
17. Saquib N, von Muhlen D, Garland CF, Barrett-Connor E. Serum 25-hydroxyvitamin D, parathyroid hormone, and bone mineral density in men: the Rancho Bernardo study. Osteoporos Int 2006; 17:1734-1741.
18. Hannan MT, Litman HJ, Araujo AB, et al. Serum 25-hydroxyvitamin D and bone mineral density in a racially and ethnically diverse group of men. J Clin Endocrinol Metab 2008; 93:40-46.
19. Holick MF, MacLaughlin JA, Doppelt SH. Regulation of cutaneous previtamin D3 photosynthesis in man: skin pigment is not an essential regulator. Science 1981; 211:590-593.
20. Harris SS. Vitamin D and African Americans. J Nutr 2006; 136:1126-1129.
21. Fu L, Yun F, Oczak M, Wong BY, Vieth R, Cole DE. Common genetic variants of the vitamin D binding protein (DBP) predict differences in response of serum 25-hydroxyvitamin D [25(OH)D] to vitamin D supplementation. Clin Biochem 2009; 42:1174-1177.
22. Cauley JA, Danielson ME, Boudreau R, et al. Serum 25-hydroxyvitamin D and clinical fracture risk in a multiethnic cohort of women: the Women's Health Initiative (WHI). J Bone Miner Res 2011; 26:2378-2388.
23. Cosman F, Morgan DC, Nieves JW, et al. Resistance to bone resorbing effects of PTH in black women. J Bone Miner Res 1997; 12:958-966.
24. Bitetto D, Fabris C, Fornasiere E, et al. Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C. Transpl Int 2011; 24:43-50.